# PROKIDNEY CORP. (PROK) · Edgar & Edgarette company card

> Prokidney (PROK) grew revenue 1075% in FY2025 to $1 million, operating margin -18478% against a -15.8% median for biological products, (no diagnostic substances), equity -301% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1850270 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/PROK) · [JSON](https://www.pops4.com/boards/company/PROK.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $893,000 |
| Revenue growth, 1 year | 1075.0% |
| Revenue growth per year | — |
| Operating margin | -18477.8% (prior year -241678.9%) |
| Net margin | -16977.8% |
| Operating cash flow | −$120M |
| Capital spending | $15M |
| Free cash flow | −$135M |
| Cash | $109M |
| Long-term debt | — |
| Total assets | $336M |
| Total equity | −$1.0B |
| Equity ÷ assets | -301.3% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -41.28 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$120.1M in FY2025); revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $893K (FY2025). Experience: revenue up 1075.0% on the year; operating margin -18477.8%, up from -241678.9%. Soundness: equity -301.3% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $7.7M and $13.8M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -18477.8% against a -15.8% median; growth 1075.0% against 21.4%.

Range logged 2026-10-30, receipt 8e59de6a105368d4, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-29 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1850270/000119312526438071/0001193125-26-438071-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/0001193125-26-342397-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1850270/000119312526342373/0001193125-26-342373-index.htm)
- 8-K · filed 2026-05-29 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1850270/000119312526248210/0001193125-26-248210-index.htm)
- 8-K · filed 2026-05-15 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/0001193125-26-225848-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/1850270/000119312526225841/0001193125-26-225841-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001850270.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1850270

## Cite

POPS4, Edgar & Edgarette: PROKIDNEY CORP. (PROK) company card, from the company's own SEC filings, accessed 2026-10-30, https://www.pops4.com/boards/company/PROK. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.